The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis

被引:7
|
作者
Xu, Wenhua [1 ,2 ]
Cui, Jiajun [1 ,3 ]
Wu, Linqing [1 ,4 ]
He, Caigu [1 ,5 ]
Chen, Gang [1 ]
机构
[1] Univ Kentucky, Dept Pharmacol & Nutr Sci, Coll Med, MN306,800 Rose St, Lexington, KY 40536 USA
[2] Univ Sci & Technol China, Dept Neurol, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China
[3] Yichun Univ, Coll Med, Dept Biochem, Yichun 336000, Jiangxi, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou 350003, Fujian, Peoples R China
[5] Fujian Univ Tradit Chinese Med, Dept Histol & Embryol, Fuzhou 361000, Fujian, Peoples R China
关键词
Arsenic; Lung; Tumor; T cell; PD-1; PD-L1; REGULATORY T-CELLS; CANCER; CD8(+); EXHAUSTION; PROLIFERATION; IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; MODELS; PD-L1;
D O I
10.1016/j.taap.2021.115633
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/ Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] PD-L1/PD-1 and arsenic lung tumorigenesis.
    Xu, Wenhua
    Chen, Gang
    CANCER RESEARCH, 2021, 81 (13)
  • [2] Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis
    Narayanapillai, Sreekanth Chanickal
    Han, Yong Hwan
    Song, Jung Min
    Kebede, Manaye Ebabu
    Upadhyaya, Pramod
    Kassie, Fekadu
    CARCINOGENESIS, 2020, 41 (11) : 1518 - 1528
  • [3] PD-1/PD-L1 checkpoint in hematological malignancies
    Annibali, O.
    Crescenzi, A.
    Tomarchio, V.
    Pagano, A.
    Bianchi, A.
    Grifoni, A.
    Avvisati, G.
    LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
  • [4] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [5] Structural basis of PD-1/PD-L1 checkpoint inhibition
    Magiera, K.
    Zak, K.
    Berlicki, L.
    Domling, A.
    Holak, T.
    Dubin, G.
    FEBS JOURNAL, 2017, 284 : 45 - 45
  • [6] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [7] Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer
    Cagle, Philip T.
    Bernicker, Eric H.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (12) : 1477 - 1478
  • [8] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [9] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
    AmeliMojarad, Mandana
    AmeliMojarad, Melika
    Cui, Xiaonan
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
  • [10] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78